This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting
T-cell malignancies can be divided into precursor (T-acute lymphoblastic leukemia/lymphoblastic lymphoma, T-ALL/LBL) and mature T-cell neoplasms, which are comprised of 28 different entities. Most of
NSG mice recived i.p. injection of 10e5 ffLuc+ OVCAR-3 tumor cells on day 0, and were treated with asingle dose of 2.5 x 10e7 CE7R-transduced T cells i.p. (day 7). Flow cytometric detection of human T